Valuation: Dimerix Limited

Market Cap 144M 103M 89.08M 84.06M 76.26M 143M 9.85B 1B 387M 5B 386M 378M 15.89B P/E 2025
-24.3x
P/E 2026 -4.13x
Enterprise Value 128M 91.44M 79.23M 74.77M 67.83M 127M 8.76B 893M 344M 4.45B 343M 336M 14.13B EV / Sales 2025
49.4x
EV / Sales 2026 16.9x
Free-Float
77.77%
Yield 2025 *
-
Yield 2026 -
1 day-4.00%
1 week-15.79%
Current month-14.29%
1 month-18.64%
3 months+45.45%
6 months-31.43%
Current year-56.36%
1 week 0.24
Extreme 0.24
0.28
1 month 0.24
Extreme 0.24
0.33
Current year 0.16
Extreme 0.157
0.56
1 year 0.16
Extreme 0.157
0.66
3 years 0.06
Extreme 0.061
0.78
5 years 0.05
Extreme 0.052
0.78
10 years 0.05
Extreme 0.052
0.78
Manager TitleAgeSince
Chief Executive Officer - 27/08/2018
Director of Finance/CFO 59 29/01/2026
Chief Tech/Sci/R&D Officer - 01/10/2023
Director TitleAgeSince
Director/Board Member 61 03/07/2015
Chairman - -
Director/Board Member - 27/08/2018
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Chairman

100,000 0.0167%
12/12/25 Free

Director

100,000 0.0167%
Change 5-day change 1-year change 3-year change Capi.($)
-4.00%-15.79%-53.40%+287.10% 108M
+0.56%-5.82%-2.45%+9.99% 45.48B
+0.66%-2.34%+340.62%+524.38% 43.68B
+1.49%-0.78%+41.90%+22.65% 43.09B
+2.11%-1.24%+9.09%+76.85% 39.4B
+0.34%-4.94%+9.34%+40.23% 31.91B
+0.53%-2.08% - - 17.31B
+1.34%+0.70%+21.35%+111.39% 16.4B
+2.07%-0.77%+13.07%+32.89% 14.24B
-1.85%-5.33%+78.63%+34.13% 13.28B
Average +0.37%-3.90%+50.91%+126.62% 26.49B
Weighted average by Cap. +1.01%-3.26%+75.94%+126.92%

Financials

2025 2026
Net sales 5.59M 3.99M 3.45M 3.26M 2.96M 5.55M 382M 38.92M 15M 194M 14.97M 14.64M 616M 6.35M 4.53M 3.93M 3.71M 3.36M 6.31M 434M 44.27M 17.06M 220M 17.03M 16.65M 701M
Net income -13.25M -9.45M -8.19M -7.73M -7.01M -13.16M -906M -92.33M -35.58M -460M -35.51M -34.73M -1.46B -29.81M -21.27M -18.43M -17.39M -15.78M -29.6M -2.04B -208M -80.04M -1.03B -79.89M -78.12M -3.29B
Net Debt -68.19M -48.65M -42.15M -39.78M -36.09M -67.7M -4.66B -475M -183M -2.37B -183M -179M -7.52B -15.92M -11.36M -9.84M -9.29M -8.43M -15.81M -1.09B -111M -42.75M -552M -42.66M -41.72M -1.76B
Logo Dimerix Limited
Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company focused on developing new therapies for kidney diseases. The Company's lead program, DMX-200, is in Phase III clinical development for focal segmental glomerulosclerosis (FSGS), a serious and life-threatening rare kidney disease with limited treatment options. In addition, it is advancing a Phase II program in acute kidney injury (AKI), further strengthening its pipeline in high-need renal indications. DMX-200 is a chemokine receptor (CCR2) antagonist administered to patients already receiving an angiotensin II type I receptor (AT1R) blocker, the standard of care treatment for hypertension and kidney disease. The Company's DMX-652 is a selective inhibitor of USP30 - a mitochondrial enzyme that slows the removal of damaged mitochondria. The Phase II trial is designed to investigate DMX-652's potential to prevent kidney injury and preserve renal function. It is also developing DMX-700 for respiratory disease.
Employees
15
Date Price Change Volume
14/09/26 A$0.2400 -4.00% 765,446
11/09/26 A$0.2500 0.00% 810,805
10/09/26 A$0.2500 -3.85% 1,392,741
09/09/26 A$0.2600 -3.70% 1,125,101
08/09/26 A$0.2700 -3.57% 815,693
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!